Literature DB >> 7701465

Necrotic, ulcerative bronchitis, the presenting feature of lymphoproliferative disease following heart-lung transplantation.

J J Egan1, P S Hasleton, N Yonan, A N Rahman, A K Deiraniya, K B Carroll, A A Woodcock.   

Abstract

Following heart-lung transplantation two of 21 patients who survived more than 100 days developed post-transplant lymphoproliferative disease. Both presented with localised ulcerative bronchitis documented at flexible bronchoscopy four months after transplantation. Histological examination showed necrosis with acute inflammation and ulceration. Case 2 demonstrated lymphoproliferative disease from biopsies subsequently taken at rigid bronchoscopy. Case 1 later developed lung nodules and a monoclonal high grade B cell non-Hodgkin's lymphoma was confirmed by an open lung biopsy. The bronchoscopic features described should alert clinicians to post-transplant lymphoproliferative disease as an underlying diagnosis and suggest that bronchus associated lymphoid tissue is the initial site for clonal proliferation in the disease.

Entities:  

Mesh:

Year:  1995        PMID: 7701465      PMCID: PMC473926          DOI: 10.1136/thx.50.2.205

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

Review 1.  B-cell lymphoma in organ transplant recipients.

Authors:  J A Thomas; D H Crawford
Journal:  Semin Thorac Cardiovasc Surg       Date:  1990-07

2.  Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression.

Authors:  J M Armitage; R L Kormos; R S Stuart; F J Fricker; B P Griffith; M Nalesnik; R L Hardesty; J S Dummer
Journal:  J Heart Lung Transplant       Date:  1991 Nov-Dec       Impact factor: 10.247

3.  Cyclosporin A immunosuppression, Epstein-Barr antibody, and lymphoma.

Authors:  J Nagington; J Gray
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

4.  Characterization of the major Epstein-Barr virus-specific RNA in Burkitt lymphoma-derived cells.

Authors:  J R Arrand; L Rymo
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

5.  Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft.

Authors:  S A Yousem; P Randhawa; J Locker; I L Paradis; J A Dauber; B P Griffith; M A Nalesnik
Journal:  Hum Pathol       Date:  1989-04       Impact factor: 3.466

6.  The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.

Authors:  M A Nalesnik; R Jaffe; T E Starzl; A J Demetris; K Porter; J A Burnham; L Makowka; M Ho; J Locker
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

7.  Bronchus associated lymphoid tissue (BALT) in human lung: its distribution in smokers and non-smokers.

Authors:  I Richmond; G E Pritchard; T Ashcroft; A Avery; P A Corris; E H Walters
Journal:  Thorax       Date:  1993-11       Impact factor: 9.139

8.  Necrotic, ulcerative bronchitis, the presenting feature of lymphoproliferative disease following heart-lung transplantation.

Authors:  J J Egan; P S Hasleton; N Yonan; A N Rahman; A K Deiraniya; K B Carroll; A A Woodcock
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

9.  Human B-cell lymphoma in severe combined immunodeficient mice after active infection with Epstein-Barr virus.

Authors:  T J Boyle; M Tamburini; K R Berend; A M Kizilbash; M J Borowitz; H K Lyerly
Journal:  Surgery       Date:  1992-08       Impact factor: 3.982

  9 in total
  2 in total

Review 1.  Management of cystic fibrosis before and after lung transplantation.

Authors:  J J Egan; A A Woodcock; A K Webb
Journal:  J R Soc Med       Date:  1997       Impact factor: 18.000

2.  Necrotic, ulcerative bronchitis, the presenting feature of lymphoproliferative disease following heart-lung transplantation.

Authors:  J J Egan; P S Hasleton; N Yonan; A N Rahman; A K Deiraniya; K B Carroll; A A Woodcock
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.